Acquisitions

NeuroPharm Inc.

Out with the Old, In with the New

Changing the way mental health treatment works, NeuroPharm Inc. (NPI) focuses on developing a proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations including veterans, EMS personnel, and other high-risk groups. Using evidence-based medicine, NPI, in collaboration with its partners, is developing a psilocybin dosing technology and establishing a therapeutic psilocybin-based treatment to address the unmet needs of high-risk populations. NPI is implementing an intellectual property strategy via patent filings, copyrights, trademarks, and other protective actions.

Mindleap Health

A Next-Generation Inner Wellness Platform

Mindleap Health’s Mindleap platform offers a unique user experience that combines therapeutic and educational content, 1-on-1 professional support for psychedelic integration and inner wellness, and a private health journal for mental health and lifestyle monitoring. The platform is designed to be highly scalable and offers a unique clinical practice management system that will continue to be built out in order to support psychedelic practitioners and organizations in unique ways. With this strategic technology acquisition, we are positioned to support psychedelic wellness as a part of the broader categories of mental health and inner wellness, in a distributed and global fashion.